Danish NMD Pharma does not have a product in development, yet has acquired DKK 280m from Novo Holdings, Lundbeckfonden, Swiss Roche Venture Fund and the Dutch venture fund Inkef Capital. It is the largest investment round in Scandinavia for such a young biotech company since the beginning of the millennium. "It is a great strength for our company that we get this backing and it gives us some peace of mind that we have the money to go forward" says CEO and co-founder Thomas Holm Pedersen. The company has discovered a method to strengthen communication between nerve and muscle so that muscle strength can be restored in muscular patients.
